Hims & Hers (NYSE: HIMS) has been on a wild journey over the past year as GLP-1s drive both big gains and big losses for the ...

Fintel reports that on January 10, 2025, Citigroup downgraded their outlook for Hims & Hers Health (NYSE:HIMS) from Neutral ...

Teladoc's growth and profitability challenges continue amid rising competition. Learn why TDOC stock remains under pressure ...

The Dow Jones Industrial Average lost 696.75 points, or 1.63%, to close at 41,938.45. The S&P 500 slid 1.54% to 5,827.04, ...

Morgan Stanley upgraded Gilead (GILD) to Overweight from Equal Weight with a price target of $113, up from $87. The firm sees ...

When it comes to the efficacy of a hair loss treatment, there’s nothing more telling than a before and after photo.

Companies seeking to benefit from campaign promises to cut regulations and taxes are ditching diversity and climate ...

Pelvic floor dysfunction — or PFD — is a term for a variety of disorders that affect the muscles in your pelvic floor. If the ...

Citigroup lowered shares of Hims & Hers Health (NYSE:HIMS – Free Report) from a neutral rating to a sell rating in a report ...